A single-arm phase II trial (NCT03556345) in patients reported clinically meaningful benefit with response rates of approximately 18% and median OS (mOS) of 7.6 months in a heavily pre-treated HER2 positive [immunohistochemistry (IHC)2+ or IHC3+] gastric/GOJ cancer population [42]. The gene discussed is ERBB2; the disease is cancer.